Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2025 Earnings Presentation
16 slides from Bactiguard Holding Ab's earnings presentation, Apr 24, 2025
Slide 1: Q1 2025 presentation
Q1 2025 presentation Thursday 24 April 2025 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q1 2025 key figures and highlights
Q1 2025 key figures and highlights Continued profitability and revenue growth Key figures for Q1 2025 (Q1 2024) Highlights • Fourth quarter in a row with positive Revenues 62.7 (58.8) MSEK EBITDA • Solid BD collaboration growth EBITDA 9.4 (-1.5) MSEK • Wound Management revenues increase Net loss 4.7
Slide 3: The issue of healthcare associated infections and why prevention matters
The issue of healthcare associated infections and why prevention matters • 1 in 10 patients worldwide affected by healthcare associated infections (HAI)1 • 40-60% of all HAIs caused by medical devices2 • Up to 50% of HAIs estimated to be preventable3 • Costs associated with HAIs (ie extended hospita
Slide 4: Focus areas and priorities
Focus areas and priorities R&D Wound License Medical Management partnerships portfolio Regulatory Advance current and develop Invest in Grow profitably and new partnerships key competencies expand into new markets 4
Slide 5: Partnership snapshot Q1 2025
Partnership snapshot Q1 2025 Exclusivity partnerships and License partnerships announced with partner name Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Cardiology Neurology Urology Vascular access Other 5
Slide 6: BD partnership update
BD partnership update Solid partnership • Collaboration spanning entire value chain – from technology license to go-to-market strategies • Attended healthcare conference in India CRITICARE 2025 • Relaunch of Bardex IC in the US • Collaboration on market registrations required to enable launches in f
Slide 7: Zimmer Biomet partnership update
Zimmer Biomet partnership update Commercialization of ZNN Bactiguard in focus • Commercialization of the ZNN Bactiguard trauma nail in Europe • Focus on regulatory processes, especially MDR for Europe • Post Market ongoing clinical trials in Europe – main study on ZNN Bactiguard (comparative study)
Slide 8: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections through effective, biocompatible solutions to improve wound healing • Revenue increase of more than 50% – driven by rise in Hydrocyn aqua sales • Certified ISO 14001 from the British Standards Institution • Consensus report on Hydrocyn aqua’s “cle
Slide 9: Total revenue grew 7% driven by License and WM
Total revenue grew 7% by driven by License and WM Revenue development SEK million First quarter (Jan-Mar) Full year RTM 261.9 265.8 20.2 19.0 16.0 10.7 60.9 67.3 Other revenues BIP portfolio Wound Management portfolio 6.7% Total license revenue 62.7 164.7 168.8 58.8 3.7 12.7 6.0 4.9 19.2 0.5 35.1 39
Slide 10: License revenue grew 12% from existing License partners
License revenue grew 12% from existing License partners License revenue development SEK million First quarter (Jan-Mar) Full year RTM 164.7 168.8 7.7 1.5 5.2 1.5 Application development partners Exclusivity partners 11.8% 155.4 162.2 License partners 35.1 39.3 2.6 0.1 0.0 0.0 32.4 39.3 2024 2025 202
Slide 11: Total operating costs (OPEX) decreased by 13%
Total operating costs (OPEX) decreased by 13% Total operating costs (OPEX) development SEK million First quarter (Jan-Mar) Full year RTM 207.9 201.4 111.5 105.2 Personnel costs Other external expenses -13.3% Other operating expenses 48.8 42.4 87.6 84.4 29.4 23.1 18.8 15.6 8.9 11.8 0.7 3.6 2024 2025
Slide 12: Continued positive EBITDA grew to SEK 9.4 million
Continued positive EBITDA grew to SEK 9.4 million EBITDA development SEK million First quarter (Jan-Mar) Full year RTM 28.9 18.0 +10.9 EBITDA 9.4 -1.5 2024 2025 2024 2024/25 12 Source: Bactiguard Holding AB, Interim report Q1 2025, p. 14
Slide 13: Cash down to SEK 47 million due to voluntary repayment
Cash down to SEK 47 million due to voluntary repayment Cash flow for the period and total cash development SEK million Incl. SEK 51 million voluntary 116.7 amortization of loan in 12.1 connection with our planned 0.1 refinancing with SEB 55.5 46.8 2.2 Cash end of 2024 Cash flow Cash flow Cash flow E
Slide 14: Q1 2025 key takeaways
Q1 2025 key takeaways Continued profitability and revenue growth • Strong start of 2025 • Fourth quarter in a row with positive EBITDA • Solid BD collaboration • Wound Management’s Hydrocyn aqua growth driver • Updated strategic and financial targets to be achieved by year-end 2030 • Five strategic
Slide 15: Questions & Answers
Questions & Answers Q1 2025 presentation Christine Lind Patrick Bach CEO CFO
Slide 16: Q&A to champion a healthier world by preventing infections
Q&A to champion a healthier world by preventing infections